Similarly, dysregulation of the m6A writer METTL3 can impact m6A modification of synaptic mRNAs (e.g., GluA1 and GluA2), altering their translation and synaptic strength in AD mouse models. This evidence concerns the gene GRIA2 and Alzheimer disease.